SAN FRANCISCO, CA, November 30, 2020 – MapLight Therapeutics today announced a $8.1 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), to undertake a large-scale, systematic investigation of the brain circuits and mechanisms that are responsible for triggering psychiatric symptoms in Parkinson’s disease. Results will inform identification of novel drug targets … Continued
Creating innovative therapeutics for serious CNS disorders
Maplight is a biopharmaceutical company discovering and developing novel therapeutics for patients with disorders of the central nervous system (CNS).
Our Motivation
Though the brain plays such a critical role in our bodies, it’s interconnections have until recently been poorly understood. Consequently, very few targeted medications have been developed to help those suffering from serious central nervous system (CNS) disorders. Significant unmet medical need persists in this area, and the field has seen little innovation in the advancement of effective therapies. More
Our Platform
We’re on the forefront of developing more effective therapeutics for CNS disorders, focusing on critical neural circuits associated with the defining symptoms of disease. More
Our Clinical Programs
We have advanced our Autism program into a Phase 1 clinical trial, with many more programs under development. More
News
Interim data from Phase 1 clinical trial with repeated dosing in healthy volunteers demonstrates positive safety and tolerability profile for ML-004 SAN FRANCISCO, November 23, 2020 – MapLight Therapeutics today announced it has completed dosing of healthy volunteers across five cohorts in a Phase 1 clinical trial evaluating the safety of ML-004, a selective serotonin … Continued